Bruce Power Receives Regulatory Approval for On-Site Isotope Processing Facility
Canada's nuclear regulator has granted Bruce Power authorization to operate its on-site hot cell facility, a crucial step in the production of lutetium-177 (Lu-177). Lu-177 is a medical isotope used in the treatment of prostate cancer and other targeted therapies within precision medicine. The Canadian Nuclear Safety Commission's approval allows Bruce Power to perform Target Carrier Removal, an essential part of the Lu-177 production process, directly at its facility. This new capability is expected to streamline isotope production, reduce transportation needs, enhance worker safety, and lower emissions. The hot cell facility, whose construction was completed in July, represents a significant milestone in Bruce Power's broader efforts to expand its medical isotope production. Bruce Power has a history of producing medical radioisotopes, including cobalt-60 since 1986, and began producing medical-grade cobalt-60 for cancer treatments in 2021. In 2022, it became the first commercial nuclear operator to produ... 
